Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From May 28, 2025

P&G Q3 Review: Miss On All Fronts; Quarterly Inconsistency Continues, Says Motilal Oswal— Maintains 'Neutral'

P&G Q3 Review: Miss On All Fronts; Quarterly Inconsistency Continues, Says Motilal Oswal— Maintains 'Neutral'
Procter & Gamble Hygiene and Health Care Q3 FY25's revenue was down 1% YoY at Rs 9.9 billion (vs 14%/10% growth in Q3 FY24/Q2 FY25). (photo Image source: company)
STOCKS IN THIS STORY
Procter & Gamble Hygiene & Health Care Ltd.
--

P&G delivered a 7% revenue CAGR during FY19-24, and the brokerage estimates a 7% CAGR during FY24-27E. The company is less predictable on a quarterly basis, but its annual performance is still quite steady. Ebitda margin has also seen consistent improvement, with 250 bp expansion during FY19-24 to ~23.5%.

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

P&G Hygiene and Healthcare Ltd.'s Q3 FY25 (FY ending June) performance missed our estimates on all fronts. We have noted such performance volatility on a quarterly basis in the past. Revenue was down 1% YoY at Rs 9.9 billion (vs 14%/10% growth in Q3 FY24/Q2 FY25).

Gross margin contracted 610 bp YoY/460 bp QoQ to 60.2% (estimate 65%). Gross profit was down by 10% YoY. Ad spends were down 10% YoY (12.2% of sales). Ebitda declined 19% YoY to Rs 2.1 billion (estimate: Rs 2.7 billion). Ebitda margin contracted 450 bp YoY and 860 bp QoQ to 21.1% (estimate: 24.7%).

P&G delivered a 7% revenue CAGR during FY19-24, and we estimate a 7% CAGR during FY24-27E. The company is less predictable on a quarterly basis, but its annual performance is still quite steady. Ebitda margin has also seen consistent improvement, with 250 bp expansion during FY19-24 to ~23.5%. We model 24%-25% Ebitda margin during FY24-27E. Ebitda saw a 10% CAGR during FY19-24, and we model a similar ~10% CAGR during FY24-27E.

The stock trades at a rich valuation of 52x/48x FY26E/FY27E P/E. We reiterate Neutral rating at a target price of Rs 15,000 (50 times Mar'27E EPS).

Click on the attachment to read the full report:

Motilal Oswal - P&G Q3FY25 Results Review.pdf
VIEW DOCUMENT

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

To continue reading this story
You must be an existing Premium User

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search